SCHEMBL31137152

SCHEMBL31137152

COC(=O)c1cc2c(cc1F)nc(N)c1cncn12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ILK Q13418 1/20 0.41
LYN P07948 10/20 0.40
BTK Q06187 10/20 0.40
LCK P06239 4/20 0.38
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 3/20 0.35
GLA P06280 2/20 0.35
GAA P10253 2/20 0.35
ABL1 P00519 1/20 0.35
EGFR P00533 1/20 0.35
FYN P06241 1/20 0.35
SRC P12931 1/20 0.35
EPHA8 P29322 1/20 0.35
FRK P42685 1/20 0.35
BLK P51451 1/20 0.35
BMX P51813 1/20 0.35
EPHB3 P54753 1/20 0.35
ERBB4 Q15303 1/20 0.35
HPGD P15428 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31136583 0.87 LCK (0.45) LYNBTKLCKKDM4EALDH1A1
SCHEMBL31136520 0.86 BTK (0.42) ILKLYNBTKLCKKDM4E
SCHEMBL31137636 0.86 LCK (0.38) LYNBTKLCKKMT2AKDM4E
SCHEMBL31040851 0.86 LCK (0.44) LCKKDM4EALDH1A1GLAGAA
SCHEMBL31026849 0.85 LYN (0.36) LYNBTKLCKKDM4EABL1
Hydrochloric Acid SCHEMBL31136255 0.84 LYN (0.35) LYNBTKLCKKDM4EABL1
SCHEMBL31500093 0.83 KDM4E (0.42) LCKKMT2AKDM4EALDH1A1GLA
SCHEMBL31238950 0.81 RAD51 (0.44) ILKKMT2AKDM4EALDH1A1GLA
SCHEMBL31137100 0.80 ILK (0.39) ILKLYNBTKLCKKMT2A
SCHEMBL31253280 0.79 ILK (0.42) ILKKMT2AKDM4EALDH1A1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 US disclosed
US-12448388-B2 PRMT5 inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2025-10-21 US disclosed
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2024-11-14 US disclosed
WO-2024220917-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2024-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT1, PRMT5, PRMT6 ILK 1199/4885LYN 2183/4885BTK 1490/4885
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT9 ILK 1959/4885LYN 2427/4885BTK 1326/4885
US-12448388-B2 PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT9 ILK 1959/4885LYN 2427/4885BTK 1326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.